In February 2011, the FDA required a black box warning, advising consumers that taking the fluoroquinolone ciprofloxacin may worsen muscle weakness in people with myasthenia gravis, causing severe difficulty breathing or even death. This was followed by a labeling requirement in February 2011, which required a black box warning advising that fluoroquinolones not be used in patients with a known history of Myasthenia gravis. Both Health Canada and the FDA have limited labeling changes to oral dosage formats (e.g. tablets) and intravenous antibiotics, stating that eye and ear drops do not seem to pose the same risk. The FDA first added a Boxed Warning to fluoroquinolones in July 2008 for the increased risk of tendinitis and tendon rupture. In February 2011, the risk of worsening symptoms for those with. The FDA recently announced that the prescription antibiotic Levaquin, and other fluoroquinolone antibiotics will now carry a new boxed warning for the exacerbation of myasthenia gravis. Exacerbation of Myasthenia Gravis: Fluoroquinolones, including CIPRO, have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Postmarketing serious adverse events, including deaths and requirements for ventilatory support, A black box warning signifies that studies have shown the drug carries a significant risk of a serious or life-threatening adverse event. The black box warning is the Medications labeled with black box warnings related to myasthenia gravis should be avoided. The Food and Drug Administration (FDA) requires this strictest warning when there is significant risk of serious or life-threatening side effects. The warning is surrounded by a black outline on the prescription container and insert. These label changes include black-box warnings for fluoroquinolones that state: WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including CIPRO®, have… In July 2008, the FDA required that a “black box” warning be added about the side effects of Levaquin and other similar antibiotics, which is the strongest warning that can be placed on a. WARNING: See full prescribing information for complete boxed warning. Fluoroquinolones, including LEVAQUIN ® , are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants [see Warnings and.